Laraway Financial Advisors Inc Has $2.09 Million Stock Holdings in Eli Lilly and Company $LLY

Laraway Financial Advisors Inc decreased its position in Eli Lilly and Company (NYSE:LLY) by 4.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,680 shares of the company’s stock after selling 114 shares during the period. Eli Lilly and Company comprises approximately 1.6% of Laraway Financial Advisors Inc’s holdings, making the stock its 17th largest holding. Laraway Financial Advisors Inc’s holdings in Eli Lilly and Company were worth $2,089,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Precedent Wealth Partners LLC lifted its position in Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after purchasing an additional 39 shares during the period. Capital Advisors Inc. OK raised its stake in shares of Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after buying an additional 429 shares in the last quarter. Family CFO Inc acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $54,000. Duquesne Family Office LLC lifted its holdings in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after acquiring an additional 32,640 shares during the period. Finally, Corient IA LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $570,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on LLY shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Saturday, September 27th. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective on the stock. in a research note on Sunday, August 17th. JPMorgan Chase & Co. dropped their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. Cantor Fitzgerald decreased their price target on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 13th. Finally, Leerink Partners reiterated a “market perform” rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $938.94.

Insider Activity

In related news, CEO David A. Ricks acquired 1,632 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Trading Up 0.7%

LLY stock opened at $845.40 on Tuesday. The business has a fifty day moving average price of $735.35 and a 200 day moving average price of $765.48. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The stock has a market capitalization of $800.14 billion, a price-to-earnings ratio of 55.25, a P/E/G ratio of 1.17 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the prior year, the business earned $3.92 earnings per share. The business’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.